HDAC2: a critical factor in health and disease

Trends in Pharmacological Sciences

Volumn 30, Issue 12, 2009, Pages 647-655

  Krämer, Oliver H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYCLOSTELLETTAMINE; CYTOKINE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; ONCOPROTEIN; SULPIRIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; BIPOLAR DISORDER; BRAIN FUNCTION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME INHIBITION; EPIGENETICS; EPILEPSY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC REGULATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MIGRAINE; MOLECULAR MECHANICS; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN LYMPHOMA; SOMATIC MUTATION; SYNAPTIC TRANSMISSION; T CELL LYMPHOMA; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BRAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; EMBRYONIC DEVELOPMENT; FEMALE; HEART; HISTONE DEACETYLASE 2; HORMONES; MUSCLE, SKELETAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 70449675089     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.09.007     Document Type: Review

References (63)

1. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
2. Hildmann C., et al. Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75 (2007) 487-497
3. Yang X.J., and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell. Biol. 9 (2008) 206-218
4. Spange S., et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell. Biol. 41 (2009) 185-198
5. Buchwald M., et al. HDACi - targets beyond chromatin. Cancer Lett. 280 (2009) 160-167
6. Haberland M., et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10 (2009) 32-42
7. Somoza J.R., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12 (2004) 1325-1334
8. Bieliauskas A.V., and Pflum M.K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37 (2008) 1402-1413
9. Klampfer L., et al. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279 (2004) 30358-30368
10. Montgomery R.L., et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21 (2007) 1790-1802
11. Haberland M., et al. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 7751-7755
12. Montgomery R.L., et al. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 7876-7881
13. Akhtar M.W., et al. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J. Neurosci. 29 (2009) 8288-8297
14. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280 (2009) 168-176
15. Chang H.H., et al. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45 (2009) 610-614
16. Colussi C., et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 19183-19187
17. Barnes P.J., and Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 373 (2009) 1905-1917
18. Hong S., et al. A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J. 23 (2009) 3539-3552
19. Heinzel T., and Krämer O.H. Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discov. Today Dis. Mechanisms 4 (2007) 277-283
20. Zhu P., et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5 (2004) 455-463
21. Zimmermann S., et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 67 (2007) 9047-9054
22. Huang B.H., et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12 (2005) 395-404
23. Harms K.L., and Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67 (2007) 3145-3152
24. Ropero S., et al. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27 (2008) 4008-4012
25. Butter F., et al. Unbiased RNA-protein interaction screen by quantitative proteomics. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 10626-10631
26. Kee H.J., et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ. Res. 103 (2008) 1259-1269
27. Nott A., et al. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 455 (2008) 411-415
28. Brandl A., et al. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell 101 (2009) 193-205
29. Osoata G.O., et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem. Biophys. Res. Commun. 384 (2009) 366-371
30. Krämer O.H., et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22 (2003) 3411-3420
31. Adenuga D., et al. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell. Mol. Biol. 40 (2009) 464-473
32. Meng F., et al. All-trans retinoic acid increases KLF4 acetylation by inducing HDAC2 phosphorylation and its dissociation from KLF4 in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 387 (2009) 13-18
33. Khan M.M., et al. PML-RARα alleviates the transcriptional repression mediated by tumor suppressor Rb. J. Biol. Chem. 276 (2001) 43491-43494
34. Atmaca A., et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 97 (2007) 177-182
35. Hait N.C., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325 (2009) 1254-1257
36. Göttlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
37. Yang S.H., and Sharrocks A.D. PIASxα differentially regulates the amplitudes of transcriptional responses following activation of the ERK and p38 MAPK pathways. Mol. Cell 22 (2006) 477-487
38. Metivier R., et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
39. Krämer O.H., et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 23 (2009) 223-235
40. Bicaku E., et al. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 68 (2008) 1513-1519
41. Backlund M.G., et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 68 (2008) 9331-9337
42. Kaler P., et al. HDAC2 deficiency sensitizes colon cancer cells to TNFα-induced apoptosis through inhibition of NF-κB activity. Exp. Cell Res. 314 (2008) 1507-1518
43. Krämer O.H., et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20 (2006) 473-485
44. Kong X., et al. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J. Mol. Cell. Cardiol. 46 (2009) 292-299
45. Trivedi C.M., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity. Nat. Med. 13 (2007) 324-331
46. Guan J.S., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009) 55-60
47. Evans N.P., et al. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am. J. Phys. Med. Rehabil. 88 (2009) 502-522
48. Rodino-Klapac L.R., et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39 (2009) 283-296
49. Su H., et al. Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Mol. Cancer Ther. 7 (2008) 1007-1012
50. Bradbury C.A., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19 (2005) 1751-1759
51. Krämer O.H., et al. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27 (2008) 732-740
52. Ye F., et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β-catenin-TCF interaction. Nat. Neurosci. 12 (2009) 829-838
53. Fritsche P., et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58 (2009) 1399-1409
54. Hanigan C.L., et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 135 (2008) 1654-1664
55. Ree A.H., et al. HDAC2 deficiency and histone acetylation. Nat. Genet. 40 (2008) 812-833
56. Mariadason J.M. Making sense of HDAC2 mutations in colon cancer. Gastroenterology 135 (2008) 1457-1459
57. Fischer A., et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007) 178-182
58. Salisbury C.M., and Cravatt B.F. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1171-1176
59. Krämer O.H., et al. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα. FASEB J. 22 (2008) 1369-1379
60. Marchion D.C., et al. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol. Cancer Ther. 8 (2009) 794-801
61. Munster P., et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 15 (2009) 2488-2496
62. Guidotti A., et al. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 30 (2009) 55-60
63. Khan N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008) 581-589